Cardiac Calcium Channel Blocker Therapy is a medical approach that plays a pivotal role in managing cardiovascular conditions. These blockers, also known as calcium antagonists, work by inhibiting the influx of calcium ions into the cardiac muscle cells, thereby reducing the workload on the heart. This therapeutic intervention is particularly beneficial in conditions such as hypertension, angina, and certain arrhythmias. By dilating blood vessels and relaxing the heart, calcium channel blockers help improve blood flow and reduce the strain on the cardiovascular system. Clinicians often prescribe these medications as part of a comprehensive treatment plan for individuals with various cardiovascular disorders. As with any medical therapy, it is essential for healthcare providers to tailor the prescription based on the patient's specific health profile and needs, ensuring optimal efficacy while minimizing potential side effects. The evolving landscape of Cardiac Calcium Channel Blocker Therapy continues to contribute significantly to advancements in cardiovascular medicine, enhancing the quality of care for patients with heart-related conditions.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India